Forest Laboratories ( FRX) has settled a patent dispute involving the antidepressant Lexapro, its best-selling drug.

The agreement with the Australian generic drug company Alphapharm doesn't affect the Lexapro patent fight with Miami-based Ivax ( IVX). The Ivax dispute goes to trial Dec. 5, and this is the most significant danger for Forest.

Investor interest in the Lexapro patent matter is so intense that Ivax issued a press release Wednesday "in response to rumors," saying that it was "not currently in discussions" with Forest over the drug. "Ivax believes it has valid claims against the Lexapro patents," the company said.

The stakes are enormous for Forest, which has suffered several research setbacks this year. For the three months ended June 30, Lexapro accounted for $460 million of the company's $674.7 million in sales.

If Forest defeats Ivax, it would enjoy at least four more years of Lexapro patent protection and perhaps as much as six extra years, says Ken Kulju of UBS Securities, in a Thursday research report to clients. "This is positive news for Forest, as it reduces litigation risk," says Kulju, who is neutral on the company.

"We believe the Lexapro patents will stand and Forest will prevail in the Ivax case," he adds. Kulju doesn't own shares of Forest, but his firm is a market maker in the stock.

Thursday's settlement with Alphapharm is "a minor positive," adds Marc Goodman of Morgan Stanley, in a research note upholding his equal-weight rating on Forest. "The bigger risk is obviously still the Ivax suit." He doesn't own shares, and his firm has had an investment-banking relationship in the last 12 months with Forest.

The deal means Alphapharm, which is owned by the German chemical and drug giant Merck KGaA, acknowledges the validity of the key Lexapro patent.

If you liked this article you might like

Are Fund Managers Better Than Their Funds?

Are Fund Managers Better Than Their Funds?

Can Regional Brokers Keep Outperforming?

Can Regional Brokers Keep Outperforming?

Wyeth Deal's Big, but Pfizer Still Needs a Blockbuster

Wyeth Deal's Big, but Pfizer Still Needs a Blockbuster

Cosmetic Surgery Stocks Keep Stiff Upper Lip

Cosmetic Surgery Stocks Keep Stiff Upper Lip

For Abbott, Diversity Remains Paramount

For Abbott, Diversity Remains Paramount